Breaking News Instant updates and real-time market news.

Q

QuintilesIMS

$76.33

1.05 (1.39%)

, CRL

Charles River

$81.08

1.03 (1.29%)

05:53
10/19/16
10/19
05:53
10/19/16
05:53

Quintiles downgraded to Hold from Buy at Jefferies

Jefferies analyst David Windley downgraded Quintiles (Q) to Hold citing concern over the revenue synergy targets from the IMS merger. Windley notes that his firm's survey work indicates sponsors remain skeptical of IMS data's value in speeding clinical trial execution. He lowered his price target for the shares to $79 from $80. The analyst's top picks in Pharmaceutical Services are Charles River (CRL), INC Research (INCR) and PRA Health (PRAH).

Q

QuintilesIMS

$76.33

1.05 (1.39%)

CRL

Charles River

$81.08

1.03 (1.29%)

INCR

INC Research

$45.00

0.5 (1.12%)

PRAH

PRA Health

$55.30

1.42 (2.64%)

  • 02

    Nov

  • 03

    Nov

  • 06

    Nov

Q QuintilesIMS
$76.33

1.05 (1.39%)

10/05/16
UBSW
10/05/16
NO CHANGE
Target $90
UBSW
Buy
Quintiles price target raised to $90 from $78 at UBS
UBS analyst Jonathan Groberg raised his price target on Quintiles to $90 from $78 following the completion of its merger with IMS Health. The analyst is positive on the stock citing its significant scale in a consolidating industry and near-term strength in its business. Groberg reiterated his Buy rating on Quintiles shares.
10/05/16
GSCO
10/05/16
INITIATION
Target $94
GSCO
Buy
Quintiles initiated with a Buy at Goldman
Goldman analyst Robert Jones removed his Not Rated designation and added Quintiles to the Buy list with a $94 price target. Jones thinks the strong CRO industry backdrop, modest improvements in win and conversion rates will result in upside to estimates/guidance.
06/28/16
UBSW
06/28/16
NO CHANGE
Target $78
UBSW
Buy
Quintiles offers compelling risk/reward, says UBS
UBS said Quintiles (Q) shares offer a compelling risk/reward. Investors are under-appreciating the near-term strength in Quintiles' business and the potential for its merger with IMS Health (IMS) to provide significant competitive advantages, said the firm, which reiterated its Buy rating and $78 price target on Quintiles shares.
07/11/16
AVON
07/11/16
UPGRADE
AVON
Outperform
Quintiles upgraded to Outperform from Market Perform at Avondale
CRL Charles River
$81.08

1.03 (1.29%)

08/18/16
RHCO
08/18/16
NO CHANGE
RHCO
Charles River reported 'strong' results, says SunTrust
SunTrust analyst Sandy Draper says that Charles River reported "strong" results, and he says that the company should benefit from synergies from its acquisition of Wil Research in the next two to three quarters. Draper keeps a Buy rating on the stock.
08/04/16
BARD
08/04/16
NO CHANGE
Target $100
BARD
Outperform
Charles River price target raised to $100 from $92 at Baird
Baird raised its price target on Charles River Labs to $100 from $92 following solid Q2 results. The firm believes the company's outlook is bright and its performance drivers were balanced, noting also that guidance was raised. Baird reiterated its Outperform rating on Charles River shares.
09/06/16
UBSW
09/06/16
DOWNGRADE
Target $78
UBSW
Sell
Charles River downgraded to Sell from Neutral at UBS
UBS analyst Jonathan Groberg downgraded Charles River Laboratories to Sell saying 2016 looks like a "peak organic growth year" for the company. The analyst sees a "number of risks" to 2017 consensus estimates. He lowered his price target for the shares to $78 from $83.
06/20/16
FBCO
06/20/16
INITIATION
Target $84
FBCO
Neutral
Charles River initiated with a Neutral at Credit Suisse
Target $84.
INCR INC Research
$45.00

0.5 (1.12%)

08/12/16
GSCO
08/12/16
UPGRADE
Target $62
GSCO
Conviction Buy
INC Research upgraded to Conviction Buy from Buy at Goldman
Goldman analyst Robert Jones added INC Research to the Conviction Buy List with a $62 price target following strong Q2 fundamental updates across the sector. Jones said INC's valuation is not reflective of the group's high growth and sees upside to Street estimates from backlog conversion and bookings growth estimates that seem too conservative.
08/02/16
RHCO
08/02/16
NO CHANGE
RHCO
INC Research reported good results, says SunTrust
SunTrust analyst Sandy Draper says he would be "hard pressed to find faults" with INC's beat and raise Q2 results. The analyst believes that the company is "well-positioned to sustain its above-industry growth" under its incoming CEO. He keeps a Buy rating on the shares.
06/20/16
FBCO
06/20/16
INITIATION
Target $51
FBCO
Outperform
INC Research initiated with an Outperform at Credit Suisse
Target $51.
05/03/16
BARD
05/03/16
DOWNGRADE
Target $51
BARD
Neutral
INC Research downgraded to Neutral from Outperform at Baird
Baird analyst Eric Coldwell downgraded INC Research to Neutral and lowered its price target to $51 from $55. The analyst said INC had a strong quarter and raised guidance but is reducing his rating due to the strong run in shares and expectations for a reversion toward sector mean on earnings growth.
PRAH PRA Health
$55.30

1.42 (2.64%)

09/22/16
SBSH
09/22/16
NO CHANGE
Target $66
SBSH
Buy
PRA Health price target raised to $66 from $55 at Citi
Citi analyst Garen Sarafian raised his price target for PRA Health Sciences to $66 after hosting investor meetings with management. PRA's recent major client win of Takeda is just now beginning to be understood, Sarafian tells investors in a research note. The analyst views Takeda as a very good fit for the company and notes that management also offered favorable commentary on margins. He keeps a Buy rating on PRA.
09/15/16
WELS
09/15/16
NO CHANGE
WELS
Street underestimating potential of PRA Health deal, says Wells Fargo
Wells Fargo believes that the Street is underestimating the potential benefit to PRA Health (PRAH) of its deal with Takeda (TKPYY). The firm expects PRA's bookings over the next year to significantly exceed the industry average, causing 2017 and 2018 consensus estimates for the company to rise. Wells raised its price target on PRA to $65-$67 from $56-$59 and keeps an Outperform rating on the shares.
09/06/16
UBSW
09/06/16
DOWNGRADE
Target $55
UBSW
Neutral
PRA Health downgraded to Neutral from Buy at UBS
UBS analyst Jonathan Groberg downgraded PRA Health Sciences to Neutral saying the current valuation leaves "less room for upside." The analyst raised his price target for the shares to $55 from $50.
08/09/16
RHCO
08/09/16
NO CHANGE
RHCO
PRA Health guidance conservative, says SunTrust
SunTrust analyst Sandy Draper says that PRA's guidance "appears conservative," given the company's better than expected results and the "potential large opportunity" embodied in its backlog. The analyst keeps a $60 price target and Buy rating on the shares.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.